In contrast to breast and prostate cancers, the present study revealed the elevated expression of CMG2 in pancreatic cancer, and the increased expression of CMG2 was associated with disease progression and poor prognosis. This evidence concerns the gene ANTXR2 and Familial prostate cancer.